(IN BRIEF) Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly improves lung function in patients with uncontrolled asthma, compared to dual-combination ICS/LABA therapy. The trials demonstrate the potential of Breztri … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alberto Papi, asthma, AstraZeneca, BioPharmaceuticals R&D, Breztri Aerosphere, budesonide/glycopyrronium/formoterol, chronic respiratory disease, clinical trials, COPD, global asthma statistics, ICS/LABA, KALOS, LOGOS, lung function, Phase III, regulatory authorities, Sharon Barr, triple-combination therapy